Zhengye Biotechnology Holding Limited

Healthcare · Drug Manufacturers - Specialty & Generic

1.20$ -1.6% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Balance Sheet

Zhengye Biotechnology Holding Limited (ZYBT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Total Assets" came in at 436 million CNY. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

Tick rows to compare them in a chart (up to 4)

Balance Sheet ZYBT
Line item	Q4 22	Q2 23	Q4 23	Q2 24	Q4 24	Q2 25	Q3 25	Q4 25	Q1 26
Total Assets	520	514	500	488	493	493	436	436	436
Current Assets	214	217	206	190	178	178	137	137	137
Cash	9.7	24	15	7.2	19	19	50	50	50
Cash & Short-Term Investments	9.7	24	16	8.5	–	20	52	–	52
Receivables	134	124	99	92	60	89	18	18	18
Inventory	55	54	58	65	58	58	39	39	39
Intangible Assets	19	18	16	25	23	23	55	55	55
Total Liabilities	163	188	161	138	141	141	130	130	130
Current Liabilities	152	177	150	137	136	136	120	120	120
Short-Term Debt	55	80	80	87	–	82	66	–	66
Accounts Payable	79	49	46	42	43	43	44	44	44
Long-Term Debt	–	10.0	10.0	–	4.8	4.7	–	8.9	–
Shareholders' Equity	296	262	273	282	284	284	250	250	250
Retained Earnings	66	31	38	47	48	48	11	-22	-22
Shares Outstanding	–	–	47	47	47	47	47	47	47

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings